Screener
4D Molecular Therapeutics FDMT Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current assets | 405,364 | 413,134 |
| Marketable securities, long-term | 66,739 | 111,379 |
| Property and equipment, net | 13,587 | 14,867 |
| Operating lease right-of-use assets, net | 17,357 | 18,143 |
| Other assets | 9,858 | 9,188 |
| Total assets | $512,905 | $566,711 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's operating lease ROU assets?
- 4D Molecular Therapeutics (FDMT) reported operating lease ROU assets of $17.36M in Q1 2026.
- How has 4D Molecular Therapeutics's operating lease ROU assets changed year-over-year?
- 4D Molecular Therapeutics's operating lease ROU assets decreased by 14.8% year-over-year, from $20.37M to $17.36M.
- What is the long-term trend for 4D Molecular Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's operating lease ROU assets has grown at a 1.9% compound annual growth rate (CAGR), from $16.5M to $18.14M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about 4D Molecular Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude